NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
13 trialsNCT01204710 2019-09-20
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00182741 2017-05-03
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00017563 2017-04-28
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00058084 2017-02-23
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003858 2016-07-13
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
Alliance for Clinical Trials in Oncology
Phase 2 Withdrawn
NCT00447473 2016-03-17
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00124566 2016-01-18
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Eisai Inc.
Phase 2 Completed
NCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT00452387 2011-09-16
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00627354 2011-05-16
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006114 2011-03-01
Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Unknown